The pharmaceutical industry and the internet: Are drug company funded depression websites biased?

Journal of Mental Health

Volumn 18, Issue 6, 2009, Pages 476-485

  Wattignar, Sarah De ^a   Read, John ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

Antidepressant medication; Depression; Internet; Pharmaceutical industry

Indexed keywords

ARTICLE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG INDUSTRY; FUNDING; INTERNET; INTERRATER RELIABILITY;

EID: 73349085900     PISSN: 09638237     EISSN: 13600567     Source Type: Journal    
DOI: 10.3109/09638230902968183     Document Type: Article

References (24)

1. Angell, M. (2004). The truth about drug companies: How they deceive us and what to do about it. New York: Random House.
2. Angermeyer, M., & Dietrich, S. (2006). Public beliefs about and attitudes towards people with mental illness: A review of population studies. Acta Psychiatrica Scandinavica, 113, 163-179.
3. Antonuccio, D.O., Burns, D.D., & Danton, W.G. (2002). Antidepressants: A triumph of marketing over science? Prevention and Treatment, 5, 25.
4. Antonuccio, D.O., Danton, W.G., & DeNelsky, G.Y. (1995). Psychotherapy versus medication for depression: Challenging the conventional wisdom with data. Professional Psychology: Research and Practice, 50, 450-452.
5. Antonuccio, D.O., Thomas, M., & Danton, W.G. (1997). A cost effective analysis of cognitive behavioural therapy and fluoxetine (prozac) in the treatment of depression. Behavioural Therapy, 28, 187-210.
6. Bekelman, J.E., Li, Y., & Gross, P.C. (2003). Scope and impact of financial conflict of interest in biomedical research. A systematic review. Journal of American Medical Associaton, 289, 454-465.
7. Choudhry, N.K., Stelfox, H.T., & Detsky, A.S. (2002). Relations between authors of clinical practise guidelines and the pharmaceutical industry. The Journal of the American Medical Association, 287, 614.
8. Cosgrove, L., Krimsky, S., Vijayaraghavan, M., & Schneider, L. (2006). Financial ties between DSM-IV panel members and the pharmaceutical industry. Psychotherapy and Psychosomatics, 75, 154-160.
9. Findlayson, G., & Mullner, R. (2005). Direct to consumer advertising of prescription drugs: Help or hindrance to the public' s health? Journal of Consumer Marketing, 22, 429-431.
10. Healy, D. & Thase, M.E. (2003). Is academic psychiatry for sale? British Journal of Psychiatry, 182, 388-391.
11. Hollon, S.D., Thase, M.E., & Markowitz, J.C. (2002). Treatment and prevention of depression. Psychological Science in the Public Interest, 3, 39-77.
12. Hunter, D. (2007). Antidepressants and the pharmaceutical companies: Corporate responsibilities. Broomall, PA: Mason Crest Publishers.
13. Kirsch, I., Deacon, B., Huedo-Medina, T., Scoboria, A., Moore, T., & Johnson, B. (2008). Initial severity and antidepressant benefits: A meta-analysis of data submitted to the Food and Drug Administration. PLOS Medicine, 5, 260-268.
14. Law, J. (2006). Big pharma: How the world's biggest drug companies control illness. London: Constable and Robinson.
15. Leo, J., & Lacasse, J. (2007). The media and the chemical imbalance theory of depression. Society, 45, 35-45.
16. Read, J. (2008). Schizophrenia, drug companies and the internet. Social Science & Medicine, 66, 99-109.
17. Read, J., & Haslam, N. (2004). Public opinion: Bad things happen and can drive you crazy. In: J. Read, L. Mosher & R. Bentall (Eds.), Models of madness: Psychological, social and biological approaches to schizophrenia (pp. 133-145). Hove, UK: runner-Routledge.
18. Schowalter, J. (2008). How to manage conflicts of interest with industry? International Review of Psychiatry 20, 127-133.
19. Sharfstein, S. (2005). Big Pharma and American psychiatry: The good, the bad, and the ugly. Psychiatric News, 40, 3.
20. Shooter, M.S. (2005). Dancing with the devil? A personal view of psychiatry's relationship with the pharmaceutical industry. Psychiatric Bulletin, 29, 81-83.
21. Tungaraza, T., & Poole, R. (2007). Influence of drug company authorship and sponsorship on drug outcomes. British Journal of Psychiatry, 191, 82-83.
22. Wazana, A. (2000). Physicians and the pharmaceutical industry, is a gift ever just a gift? Journal of the American Medical Association, 283, 373-380. (Pubitemid 30051756)
23. Weber, L. (2006). Profits before people? Ethical standards and the marketing of prescription drugs. Bloomington: Indiana University Press.
24. Ziegler, M.G., Lew, P., & Singer, B.C. (1995). The accuracy of drug information from pharmaceutical sales representatives. Journal of the American Medical Association, 273, 1296-1298.